Navigation Links
Blizzard, McCarthy & Nabers Launches

Informs Public of Serious Risks Associated with Use of Reglan and Metoclopramide: Provides Solutions for Legal Recourse

HOUSTON, March 9 /PRNewswire-USNewswire/ -- Blizzard, McCarthy & Nabers, one of the nation's leading pharmaceutical litigation firms is proud to announce the launch of, an educational website aimed at informing consumers of the risks associated with the use of the drug Reglan, and its generic form, metoclopramide.  As a resource for the millions of Americans who use this drug, is regularly updated with the latest news and medical information surrounding the medication and its causal link to debilitative movement disorders.

Long-term use of Reglan and generic forms of metoclopramide has been linked to Tardive Dyskinesia, a serious involuntary and repetitive movement disorder that is often irreversible. A recent study cited by the FDA, reports the prevalence of Tardive Dyskinesia at 20 percent among patients treated with Reglan for at least 12 weeks. In February 2009, the FDA issued a Black Box warning against continued use of Reglan to treat gastrointestinal disorders. is meant to provide consumers with the critical information denied to them by the pharmaceutical manufacturers marketing these drugs.  For those consumers who have already been disabled by these products, provides an avenue to seek legal redress.  Corporations that operate with an eye on the bottom line rather than the safety of their consumers must be held accountable for their actions.  For more information, visit

"As attorneys, we've seen first hand the damage that can be done by these powerful and dangerous drugs," said Scott Nabers, partner at Blizzard, McCarthy & Nabers.  "Consumers were misinformed about the risks associated with this product and many have been permanently disabled.  It is our hope that this website will provide consumers with critical information so that future patients can avoid these troubling side effects."

In January, the firm launched to provide information and avenues to legal recourse for consumers poisoned by zinc in denture cream.

Blizzard, McCarthy & Nabers, LLP, one of the nation's leading pharmaceutical litigation firms, represents thousands of clients harmed by dangerous drugs and medical devices and has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical. 

SOURCE Blizzard, McCarthy & Nabers, LLP

Back to top



SOURCE Blizzard, McCarthy & Nabers, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
2. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
3. P&M Corporate Finance and Robin Young Announce 2010 Spine Technology Summit
4. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
5. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
6. UBM Announces Plans for Japan Pharma & Bio Events
7. Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
8. Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review
9. China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Aurora Womens Pavilion Center for Sexual Health & Wellness Receives Grant to Treat Vulvar Pain
Post Your Comments:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):